Terumo Gets Its Toe Wet in the US Cardiovascular Market
Terumo is a major device company in Japan, but has to date had little success in building a US business. With the acquisition of 3M's cardiovascular business, is Terumo taking its first major step toward building a greater US presence?
You may also be interested in...
Brief summaries of recent product and clinical developments in the device industry, including developments in Cardiac and Peripheral Devices, Miniature Robotic Devices, and Diabetes Management.
The EU’s special provisions for speeding new products towards approval proved more popular than ever with drug sponsors last year.
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.